Soligenix regains oral BDP rights from Sigma-Tau

Soligenix regained the rights to market an oral formulation of beclomethasone dipropionate in Europe and North America after amending a collaboration deal with Sigma-Tau Pharmaceuticals. Beclomethasone dipropionate is a topically active corticosteroid being developed for Crohn's disease in children, gastrointestinal graft-versus-host disease and acute radiation enteritis.

View Full Article in:

Proactive Investors · Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA